SG
EDIT icon

StoneX Group’s Editas Medicine EDIT Stock Holding History

StoneX Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.1K Buy
+16,213
New +$47.4K ﹤0.01% 1225
2026
Q1 		– Sell
-15,855
Closed -$32.5K – 999
2025
Q4 		$32.5K Buy
+15,855
New +$45.8K ﹤0.01% 950

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

StoneX Group's EDIT Position: Q2 2026 in Review

StoneX Group opened a new position in Editas Medicine (EDIT) in Q2 2026: 16,213 shares worth $51.1K. The stake represents ﹤0.01% of the portfolio and ranks #1225 among its holdings. This is a return to the name: StoneX Group previously reported a position in EDIT as recently as Q4 2025.

StoneX Group first reported a position in EDIT in Q4 2025 and has held it in 2 quarters since. 216 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • StoneX Group held 16,213 shares of Editas Medicine worth $51.1K as of Q2 2026.
  • Editas Medicine was a new StoneX Group position in Q2 2026.
  • Editas Medicine made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1225 holding.
  • StoneX Group first reported a position in Editas Medicine in Q4 2025 and has held it in 2 quarters since.
  • 216 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.